A 25-year-old woman with type 2 diabetes and liver disease

Anders Ellekær Junker; Lise Lotte Gluud; Jens Pedersen; Jill Levin Langhoff; Jens Juul Holst; Filip Krag Knop; Tina Vilsbøll

doi:10.1159/000369968

A 25-year-old woman with type 2 diabetes and liver disease

Anders Ellekær Junker, Lise Lotte Gluud, Jens Pedersen, Jill Levin Langhoff, Jens Juul Holst, Filip Krag Knop, Tina Vilsbøll

Endocrinology and Metabolism

1 Citation (Scopus)

Abstract

A 25-year-old female nurse was referred to our diabetes outpatient clinic with poorly controlled type 2 diabetes, obesity and elevated liver function tests (LFTs). Following a liver biopsy she was diagnosed with non-alcoholic steatohepatitis (NASH) and liver fibrosis. Treatment with subcutaneous injections of the glucagon-like peptide-1 receptor (GLP-1R) agonist liraglutide was initiated. After 46 weeks of treatment the patient had lost 16 kg, glycemic control was excellent and LFTs had normalized. Repeat liver biopsy and ultrasound showed reduction in hepatic fat content and inflammatory cells. The biopsy no longer fulfilled the criteria for NASH. The liver biopsies did not express hepatic GLP-1Rs using quantitative polymerase chain reaction. Our case suggests that liraglutide may benefit patients with NASH.

Original language	English
Journal	Case Reports in Gastroenterology
Volume	8
Issue number	3
Pages (from-to)	398-403
Number of pages	6
ISSN	1662-0631
DOIs	https://doi.org/10.1159/000369968
Publication status	Published - 12 Apr 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1159/000369968

Cite this

@article{b3b97682cbc04d638b4a4a7b422eb8ab,

title = "A 25-year-old woman with type 2 diabetes and liver disease",

abstract = "A 25-year-old female nurse was referred to our diabetes outpatient clinic with poorly controlled type 2 diabetes, obesity and elevated liver function tests (LFTs). Following a liver biopsy she was diagnosed with non-alcoholic steatohepatitis (NASH) and liver fibrosis. Treatment with subcutaneous injections of the glucagon-like peptide-1 receptor (GLP-1R) agonist liraglutide was initiated. After 46 weeks of treatment the patient had lost 16 kg, glycemic control was excellent and LFTs had normalized. Repeat liver biopsy and ultrasound showed reduction in hepatic fat content and inflammatory cells. The biopsy no longer fulfilled the criteria for NASH. The liver biopsies did not express hepatic GLP-1Rs using quantitative polymerase chain reaction. Our case suggests that liraglutide may benefit patients with NASH.",

author = "Junker, {Anders Ellek{\ae}r} and Gluud, {Lise Lotte} and Jens Pedersen and Langhoff, {Jill Levin} and Holst, {Jens Juul} and Knop, {Filip Krag} and Tina Vilsb{\o}ll",

year = "2014",

month = apr,

day = "12",

doi = "10.1159/000369968",

language = "English",

volume = "8",

pages = "398--403",

journal = "Case Reports in Gastroenterology",

issn = "1662-0631",

publisher = "S Karger AG",

number = "3",

}

TY - JOUR

T1 - A 25-year-old woman with type 2 diabetes and liver disease

AU - Junker, Anders Ellekær

AU - Gluud, Lise Lotte

AU - Pedersen, Jens

AU - Langhoff, Jill Levin

AU - Holst, Jens Juul

AU - Knop, Filip Krag

AU - Vilsbøll, Tina

PY - 2014/4/12

Y1 - 2014/4/12

N2 - A 25-year-old female nurse was referred to our diabetes outpatient clinic with poorly controlled type 2 diabetes, obesity and elevated liver function tests (LFTs). Following a liver biopsy she was diagnosed with non-alcoholic steatohepatitis (NASH) and liver fibrosis. Treatment with subcutaneous injections of the glucagon-like peptide-1 receptor (GLP-1R) agonist liraglutide was initiated. After 46 weeks of treatment the patient had lost 16 kg, glycemic control was excellent and LFTs had normalized. Repeat liver biopsy and ultrasound showed reduction in hepatic fat content and inflammatory cells. The biopsy no longer fulfilled the criteria for NASH. The liver biopsies did not express hepatic GLP-1Rs using quantitative polymerase chain reaction. Our case suggests that liraglutide may benefit patients with NASH.

AB - A 25-year-old female nurse was referred to our diabetes outpatient clinic with poorly controlled type 2 diabetes, obesity and elevated liver function tests (LFTs). Following a liver biopsy she was diagnosed with non-alcoholic steatohepatitis (NASH) and liver fibrosis. Treatment with subcutaneous injections of the glucagon-like peptide-1 receptor (GLP-1R) agonist liraglutide was initiated. After 46 weeks of treatment the patient had lost 16 kg, glycemic control was excellent and LFTs had normalized. Repeat liver biopsy and ultrasound showed reduction in hepatic fat content and inflammatory cells. The biopsy no longer fulfilled the criteria for NASH. The liver biopsies did not express hepatic GLP-1Rs using quantitative polymerase chain reaction. Our case suggests that liraglutide may benefit patients with NASH.

U2 - 10.1159/000369968

DO - 10.1159/000369968

M3 - Journal article

C2 - 25606030

SN - 1662-0631

VL - 8

SP - 398

EP - 403

JO - Case Reports in Gastroenterology

JF - Case Reports in Gastroenterology

IS - 3

ER -

A 25-year-old woman with type 2 diabetes and liver disease

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this